The non–MLL-r blood cancer cells (including AML, ALL, and lymphoma) exhibited comparable IC50 values (green; 8.2 to 22.2 μM) to the MLL-r leukemia cells, expanding the utility of Cpd_DC60 as a therapeutic agent for a broader spectrum of hematopoietic cancers. Here, KMT2A is linked to acute myeloid leukemia.